CRIS Current Research Information System

ROSTI, GIANANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.621
EU - Europa 5.171
AS - Asia 2.843
AF - Africa 342
SA - Sud America 25
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 4
Totale 16.018
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.598
GB - Regno Unito 1.833
CN - Cina 1.036
SE - Svezia 784
IT - Italia 648
VN - Vietnam 642
DE - Germania 639
SG - Singapore 584
IN - India 308
UA - Ucraina 248
IE - Irlanda 212
RU - Federazione Russa 205
FR - Francia 200
ZA - Sudafrica 129
EE - Estonia 123
TG - Togo 110
JP - Giappone 83
JO - Giordania 68
CH - Svizzera 66
BG - Bulgaria 64
CI - Costa d'Avorio 43
NG - Nigeria 39
BE - Belgio 32
FI - Finlandia 31
ID - Indonesia 23
CA - Canada 22
GR - Grecia 22
IR - Iran 18
NL - Olanda 17
TR - Turchia 17
SC - Seychelles 15
BR - Brasile 11
AU - Australia 10
AT - Austria 9
HK - Hong Kong 9
LB - Libano 9
RO - Romania 9
TW - Taiwan 8
CL - Cile 7
KR - Corea 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 5
PL - Polonia 5
IL - Israele 4
AR - Argentina 3
EG - Egitto 3
EU - Europa 3
IQ - Iraq 3
NO - Norvegia 3
NP - Nepal 3
PT - Portogallo 3
TH - Thailandia 3
BD - Bangladesh 2
BO - Bolivia 2
EC - Ecuador 2
ES - Italia 2
LT - Lituania 2
MA - Marocco 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
RS - Serbia 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
HR - Croazia 1
KE - Kenya 1
KZ - Kazakistan 1
LV - Lettonia 1
MX - Messico 1
PK - Pakistan 1
SI - Slovenia 1
Totale 16.018
Salva come PNG Salva come JPEG
Città #
Southend 1.692
Fairfield 1.032
Chandler 793
Ashburn 597
Woodbridge 543
Singapore 517
Houston 497
Wilmington 487
Seattle 470
Dong Ket 406
Cambridge 347
Princeton 329
Ann Arbor 317
Dublin 212
Boardman 201
Nanjing 165
Westminster 145
Padova 131
Jacksonville 130
Beijing 126
Santa Clara 114
Bologna 110
Lomé 110
Berlin 92
Saint Petersburg 73
Tokyo 69
Amman 68
Jinan 68
New York 67
Sofia 64
Shenyang 62
Turin 62
Bern 59
San Diego 54
Nanchang 53
Hebei 51
Changsha 48
Falls Church 45
Abidjan 43
Jiaxing 42
Abeokuta 39
Milan 36
Bremen 33
Brussels 32
Medford 32
Redmond 32
Tianjin 32
Helsinki 30
Mülheim 27
Norwalk 26
Dearborn 25
Florence 25
Guangzhou 24
Des Moines 22
Zhengzhou 22
Haikou 20
Jakarta 20
Hangzhou 17
Shanghai 17
Taizhou 17
Rome 16
Mahé 15
Mountain View 15
Redwood City 15
Washington 15
Los Angeles 14
Bühl 12
Chengdu 12
Ningbo 12
Olalla 11
Taiyuan 11
Toronto 11
Verona 11
Istanbul 10
Kuban 10
Lanzhou 10
London 10
Wuhan 10
Castelfranco Emilia 9
Hyderabad 9
San Venanzo 9
Andover 8
Bradford 8
Frankfurt am Main 8
Harbin 8
Kunming 8
Abano Terme 7
Forlì 7
Paris 7
Frankfurt Am Main 6
Groningen 6
Pune 6
São Paulo 6
Buffalo 5
Foshan 5
Leawood 5
Phoenix 5
Piacenza 5
Prineville 5
Zanjan 5
Totale 11.386
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 333
Consensus conference on the management of tumor lysis syndrome. 229
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 217
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 216
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 216
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 208
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 205
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 199
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 183
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 174
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 173
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 167
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 165
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 165
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 164
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 162
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 160
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 155
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 142
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 141
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 139
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 134
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 130
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 130
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 129
Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. 129
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 128
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 128
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. 127
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 125
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 125
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 124
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 123
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. 123
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 123
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 123
null 122
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 120
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 119
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 118
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 117
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 115
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 114
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 112
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia 112
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 112
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 112
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 111
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 111
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 110
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 110
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 110
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 109
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 108
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 108
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 108
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 107
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 106
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 106
Leucemia mieloide cronica: terapia molecolare 105
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 105
null 104
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 103
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 103
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. 102
null 102
Diagnosis and classification of the risk 102
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 102
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 101
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 101
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 100
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 100
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 100
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 99
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 98
A review of the European LeukemiaNet recommendations for the management of CML 97
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 97
Explaining the in vitro and in vivo differences in leukemia therapy. 95
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 95
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 95
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 94
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib 94
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients 94
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors 92
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 92
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 92
Imatinib mesylate in the treatment of hematologic malignancies. 92
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. 91
Dual tyrosine kinase inhibitors in chronic myeloid leukemia. 91
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 91
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 91
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 90
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 90
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 90
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 89
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry 89
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 88
Safety profiles of first-line TKIS and managing adverse effects 87
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 86
Totale 12.378
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.934
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.934
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.376 0 0 0 0 492 426 551 558 593 303 173 280
2020/20212.281 418 181 55 82 43 83 48 141 240 95 177 718
2021/20222.827 342 88 200 257 269 171 53 177 110 193 463 504
2022/20233.154 383 505 175 385 225 225 124 173 511 65 249 134
2023/2024895 48 135 54 89 72 220 49 50 22 51 67 38
2024/20251.403 105 505 289 214 290 0 0 0 0 0 0 0
Totale 16.455